BioCentury
ARTICLE | Company News

Diaxonhit, Allergan, Bristol-Myers deal

February 18, 2013 8:00 AM UTC

Diaxonhit said it was notified by Bristol-Myers that the pharma decided not to continue development of AGN-209323 ( EHT/AGN 0001) and returned rights to the program to Allergan. BMS had rights to the...